Media Articles Related to Epirubicin
Breast cancer metastasis in postpartum mice promoted by wound healing response
Source: Breast Cancer News From Medical News Today [2014.09.26]
Within the first 5 years after the birth of a child, women are at an increased risk of developing metastatic breast cancer.
Breast cancer: most women who remove healthy breast 'happy with their decision'
Source: Breast Cancer News From Medical News Today [2014.09.25]
Women with cancer in one breast often remove the other, despite most studies suggesting they will not live longer. A new study investigates how such women feel about their choice.
Skirt size increase linked to 33% greater postmenopausal breast cancer risk
Source: Breast Cancer News From Medical News Today [2014.09.25]
Going up a skirt size over a period of 10 years between your mid 20s and mid 60s is linked to a 33% greater risk of developing breast cancer after the menopause, finds a large observational study...
Increasing Skirt Sizes May Hike Your Breast Cancer Risk: Study
Source: MedicineNet Menopause Specialty [2014.09.25]
Title: Increasing Skirt Sizes May Hike Your Breast Cancer Risk: Study
Category: Health News
Created: 9/24/2014 7:36:00 PM
Last Editorial Review: 9/25/2014 12:00:00 AM
Breast-Feeding Cuts ER-Neg Breast Cancer Risk in Black Women
Source: Medscape Hematology-Oncology Headlines [2014.09.24]
Breast-feeding might lower the risk for aggressive breast cancer in black women in the United States, a finding that can be 'acted upon,' say researchers.
Medscape Medical News
Published Studies Related to Epirubicin
Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. [2011.08.20]
PURPOSE: The Docetaxel Epirubicin Adjuvant (DEVA) trial evaluated the efficacy and toxicity of incorporating docetaxel after epirubicin to create a sequential anthracycline-taxane regimen in early breast cancer... CONCLUSION: These results suggest, within a relatively small trial, that substitution of docetaxel for epirubicin for the last three cycles of chemotherapy results in improved outcome in postmenopausal women with node-positive, early breast cancer compared with six cycles of epirubicin monotherapy.
Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy. [2011.07]
An increased dose-intensity can be achieved by either higher dose of chemotherapy per cycle (dose-escalation) or by shortening the interval between cycles (dose-dense). This multicenter randomized phase II study assessed the efficacy and safety of two different approaches: epirubicin 110 mg/m(2) combined with paclitaxel 200 mg/m(2) every 21 days and epirubicin 75 mg/m(2) combined with paclitaxel 175 mg/m(2) every 10 days, both supported with G-CSF...
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. [2011.04.27]
CONCLUSION: TP53 and CHEK2 mutations were associated with lack of response to epirubicin monotherapy. In contrast, TP53 mutations and MDM2 309G allele status conferred poor disease-specific survival among patients treated with primary paclitaxel but not epirubicin monotherapy.
A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. [2011.04.12]
BACKGROUND: To evaluate activity and tolerability of two anthracycline-containing regimens as first-line treatment for anthracycline-naive relapsed breast cancer patients... CONCLUSIONS: Both anthracycline- containing regimens evaluated in the present study seem to be active and with a satisfactory tolerability in anthracycline-naive relapsed breast cancer patients.
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. [2011.02.15]
BACKGROUND: This randomised phase II study compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the conventional treatment D/prednisone (P) in advanced castrate-resistant prostate cancer (CRPC) patients... CONCLUSION: The treatment of advanced CRPC with weekly D combined with weekly EPI was feasible and tolerable, and led to superior PFS than the treatment with 3-weekly D and oral P.
Clinical Trials Related to Epirubicin
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer [Terminated]
The purpose of this study is to compare two combinations of drugs, epirubicin given with a
taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to
see if one of the combinations is better at preventing or delaying the time for breast cancer
recurrence and death after 3 years. The study will also evaluate the side effects of both
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors [Recruiting]
This is an open-label, four-arm, Phase I, dose escalation study to evaluate the safety and
tolerability and to determine the optimal tolerated regimen (OTR) of pazopanib in
combination with epirubicin or doxorubicin in patients with advanced solid tumors. Patients
will be enrolled in cohorts of 3 to receive escalating doses of pazopanib and epirubicin or
doxorubicin. Dose escalation schemas for each study arm are described in the protocol. For
each arm, the OTR will be defined as the highest dose combination of the agents where no
more than one out of six patients experiences a dose-limiting toxicity. Six to twelve
additional patients in each arm will be studied with the OTR to evaluate toxicity and
pharmacokinetics. This will allow an assessment of potential drug-drug interactions.
Antitumor activity will be assessed using RECIST criteria.
Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients [Recruiting]
The combination of taxanes, and especially docetaxel, with an anthracycline seems to be an
important part of the chemotherapy regimens used in the adjuvant setting of patients with
early-stage node-positive breast cancer patients. Whether sequential or concurrent
administration of these drugs is preferable is not yet known, especially in patients with
node-negative high risk tumors.
Study of Docetaxel in Breast Cancer Patients [Completed]
- To compare the disease free survival (DFS) in patients treated with the sequential
epidoxorubicin, cyclophosphamide, methotrexate, and fluorouracil (CMF) regimen to that
in patients treated with the same treatment plus docetaxel given sequentially after
- To compare the DFS in patients treated with the sequential epidoxorubicin, docetaxel and
CMF (only patients with > or = 4 lymph nodes) regimen to that in patients treated with
sequential intensified epidoxorubicin/docetaxel/high dose (HD) cyclophosphamide regimen
- To evaluate the overall survival in each arm
- To evaluate the tolerability of a sequential intensified
epidoxorubicin/docetaxel/HD-cyclophosphamide (arm C)
- To compare the safety of a sequential epidoxorubicin/docetaxel/CMF (arm B) regimen
versus a standard sequential epidoxorubicin/CMF regimen (arm A)
Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients [Recruiting]
This is an adjuvant, open, prospective, randomized study to compare:
A. Individually tailored and two weekly dosed epirubicin + cyclophosphamide followed by a
three weeks break followed by biweekly and tailored docetaxel (dtEC→dtT) given every second
B. Fixed dosed and three weekly epirubicin, cyclophosphamide and 5-fluorouracil, followed by
fixed dosed and three weekly docetaxel (FEC→T).
Patients with primary node-positive or high risk lymph node negative breast cancer will be
eligible for the study.
The primary objective of the phase 3 study is to compare breast cancer relapse-free survival
(BCRFS) between the dtEC→dtT and FE100C→T. To detect a five-year BCRFS difference of 0. 710
to 0. 790 about 762 patients per arm will be needed. They will be recruited during three
years and followed another two years for breast cancer events.
Secondary objectives are to compare
1. Distant disease-free survival (DDFS)
2. Event-free survival and
3. Overall survival
4. Health-related quality of life
5. Outcome in relation to tumour biological factors and polymorphism patterns
Tumour tissue will be obtained and stored for studies of prognostication and therapy
Reports of Suspected Epirubicin Side Effects
Febrile Neutropenia (16),
Death (9), more >>